Skip to main content

User account menu

Log In
Contact Us

Search

Enter the terms you wish to search for.

Main navigation

Community
Events
Publications
Membership
Awards
Sponsor
- CRS Industry Sponsors
About CRS

EnGeneIC Limited

Works

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

Professionally managed by Association Headquarters, a charter accredited association management company.

Copyright © 2024 Controlled Release Society. All Rights Reserved.